BridgeBio Pharma, Inc Earning Date (BBIO)

USA |NASDAQ |USD

BBIO Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $-0.66
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $54.02M

Bridgebio Pharma, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

BBIO Earnings Date & History Chart

BBIO Earnings & Revenue Forecast

BBIO Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 8 $-3.67 $-5.03 $-2.69

BBIO Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 1 / 2 $-3.58 $-3.53 $-3.98

BBIO Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 8 $115.99M $18.52M $316.75M

BBIO Earnings Date & Revenue History

BBIO Earnings History

|
Show More
Show More

BBIO Revenue History

|
Show More
Show More

Bridgebio Pharma, Inc Next Earnings Date & Report

BBIO Next Earnings Date & Report Preview: Jun 2022 (FQ)

BBIO's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Bridgebio Pharma, Inc Previous Earnings Dates & Reports

BBIO Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Bridgebio Pharma, Inc's previous earnings date was May 4, 2022 for its fiscal quarter ended Mar 31, 2022.

BBIO Previous Earnings Date & Report Recap: Dec 2021 (FY)

Bridgebio Pharma, Inc's previous annual earnings date was Feb 24, 2022 for its fiscal year ended Dec 31, 2021.

BBIO's earnings per share (EPS) was $-3.91, missing the consensus analysts forecast of $-3.65 by 7.12% , and lower than the previous year's EPS (Dec 2020) by 2.89%.

Revenues were $69.72M, worse than the forecast of $110.40M by -36.85%, and up by 745.14% from previous year's revenue.

The company reported a net income of $-562.54M.

Bridgebio Pharma, Inc reported a free cash flow of $-511.18M for its fiscal year, compared to $-407.23M a year ago.

The company ended the fiscal year with $1.73B in total debt, an increase of 258.79% compared to the previous year.